Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

NCT00309556 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

536

Enrollment

NETWORK

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Epirubicin
DRUG: Docetaxel
DRUG: Capecitabine
DRUG: Trastuzumab

Sponsor

Austrian Breast & Colorectal Cancer Study Group

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]